Vertex Pharmaceuticals Incorporated
Reshma Kewalramani (CEO & President) sells VRTX shares
AI-generated summary
Reshma Kewalramani, CEO & President, Director of Vertex Pharmaceuticals Incorporated Common Stock, sold 11,866 shares of Common Stock at an average price of $531.53 for a total value of $6,307,134.98 on November 6, 2026. The transaction was made under a Rule 10b5-1 trading plan adopted on 8/5/2026. Following the transaction, the insider directly holds 86,471 shares of Common Stock.
Key facts
- Insider
- Reshma Kewalramani · CEO & President, Director
Rule 10b5-1 plan
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | S · open-market saleFootnotes F1 | −11,866 | $531.53 | $6,307,134.98 | 86,471 | Direct |
Footnotes
- F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 8/5/2026.
More VRTX filings
- 144
Filed Nov 6, 2026
- 10-Q
Filed Nov 3, 2026
- 8-K
Filed Nov 2, 2026
- 4
Filed Oct 22, 2026
- 3
Filed Oct 22, 2026
- 8-K
Filed Oct 20, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.